Selective Inhibitors of HPV-E6 for Cancer Therapy

Back to all technologies
Download as PDF
2021-DAVI-69305
Researchers at Purdue University have developed inhibitors of the oncogenic E6 Protein of human papillomavirus (HPV). The HPV-E6 protein is required for tumor progression and is instrumental in immune response evasion and cancer cell proliferation. HPV-E6 is a particularly attractive therapeutic target because it is present only in malignant cells and not in healthy cells. The Purdue researchers developed E6 inhibitors using computational modeling and in vitro binding assays. These inhibitors of HPV-E6 are a proof of concept that paves the way for a first-in-class drug that will offer patients with HPV-associated tumors an alternative to radiation, chemotherapy, or surgery to improve quality of life and reduce mortality

Advantages:
-Selective targeting of the HPV-E6 protein
-First-in-class
-Does not affect healthy cells
-Offers patients an alternative to radiation/chemotherapy
-Potential reductions of mortality/morbidity

Applications:
-Therapy for patients with HPV-associated tumors

Technolog Validation: This technology has been validated through computational modelling and ligand binding assays.
Dec 17, 2020
Provisional-Gov. Funding
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org